Hyperion Therapeutics Inc (HPTX) 45.99 $HPTX
Stratos Group Adds Life Sciences Leader to Advisory Board
PR Newswire - Thu Nov 19, 2:21PM CST
Stratos Group today announced the addition of Chris Rivera to its Board as a Life Science Advisor.
HPTX: 45.99 (+0.02)
National Association of Professional Women Inducts Kamal Sigel, Vice President of Hyperion Therapeutics, Inc., Into its VIP Professional Woman of the Year Circle
PRWeb - Mon Aug 10, 11:01PM CDT
The National Association of Professional Women (NAPW) honors Kamal Sigel as a 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized with this prestigious distinction for leadership in business. NAPW is the nation's leading networking organization exclusively for professional women, boasting more than 700,000 members and over 200 operating Local Chapters.
HPTX: 45.99 (+0.02)
Hepatic Encephalopathy Therapeutics Pipeline Review, H1 2015 - 4 Companies & 5 Drug Profiles
M2 - Mon Jun 08, 10:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/std5dn/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Hyperion Therapeutics, Inc. - Ocera Therapeutics, Inc. - Umecrine Cognition AB Drug Profiles - CVXL-0060 - glycerol phenylbutyrate - ornithine phenylacetate - rifaximin - THDP-17 For more information visit http://www.researchandmarkets.com/research/std5dn/hepatic
OCRX: 2.57 (-0.03), HPTX: 45.99 (+0.02)
Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 2:08PM CDT
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2015 earnings of $1.65 per share, substantially lower than the Zacks Consensus Estimate of $1.95.
JAZZ: 150.53 (-0.44), CNCE: 11.82 (+0.33), HPTX: 45.99 (+0.02)
ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 10:20AM CDT
ARIAD Pharmaceuticals (ARIA) reported a first-quarter 2015 loss of 28 cents per share, a penny wider than the Zacks Consensus Estimate of a loss of 27 cents.
VRX: 20.95 (+0.06), PFE: 36.90 (-0.41), ARIA: 9.68 (-0.03), HPTX: 45.99 (+0.02)
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 07, 2:45PM CDT
Horizon Pharma (HZNP) is scheduled to report first-quarter 2015 results before the opening bell on May 8.
IPXL: 31.15 (-0.27), ACT: 298.98 (-2.94), HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Completes Acquisition of Hyperion Therapeutics, Inc.
Marketwired - Thu May 07, 11:45AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed the acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma to acquire all outstanding common stock of Hyperion Therapeutics in tender offer at USD46.00 per share
M2 - Thu May 07, 3:06AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) on Thursday updated the results of its tender offer to acquire all of the outstanding shares of common stock of Hyperion Therapeutics (NASDAQ: HPTX) for USD46.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, if any.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Results of Tender Offer
Marketwired - Thu May 07, 1:45AM CDT
Horizon Pharma plc ("Horizon"
(NASDAQ: HZNP) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. ("Hyperion" (NASDAQ: HPTX) for $46.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, if any. The tender offer is being effected by Horizon's indirect subsidiary, Ghrian Acquisition Corp.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Waiver of Financing Proceeds Condition
Marketwired - Thu Apr 30, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that its affiliates, Horizon Pharma, Inc. ("Parent" and Ghrian Acquisition, Inc. ("Purchaser" , waived the "Financing Proceeds Condition" described in the Offer to Purchase in connection with the previously announced tender offer to acquire all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) ("Hyperion" for $46.00 per share in cash, net to the seller in cash, without interest and less any applicable withholding taxes, if any. The tender offer is scheduled to expire at 12:01 a.m. (New York City time) on Thursday, May 7, 2015, unless further extended or earlier terminated. All other terms and conditions of the tender offer remain unchanged, including, without limitation, the "Minimum Condition" described in the Offer to Purchase.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma reports expiry of HSR Waiting Period for planned acquisition of Hyperion Therapeutics
M2 - Thu Apr 30, 3:07AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) reported on Wednesday the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR" with respect to its proposed acquisition of Hyperion Therapeutics (NasdaqGS:HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Expiration of HSR Waiting Period for Proposed Hyperion Therapeutics, Inc. Acquisition
Marketwired - Wed Apr 29, 4:48PM CDT
Horizon Pharma plc (NASDAQ: HZNP) today announced the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR" expired effective Tuesday, April 28, 2015 with respect to its proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes
Marketwired - Fri Apr 24, 3:05PM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary (the "Issuer" , has priced its offering of $475 million aggregate principal amount of 6.625% senior notes due 2023. The note offering is expected to close on or about April 29, 2015. The size of the offering was increased above the previously-announced size of $300 million aggregate principal amount of notes. As a result of the increased size of the note offering, Horizon Pharma, Inc. ("HPI" , the parent of the Issuer and a wholly-owned subsidiary of Horizon, expects that the aggregate principal amount of its previously-announced new term loan facility will be reduced from $500 million to $400 million.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion Therapeutics, Inc. Over the Proposed Sale of the Company to Horizon Pharma, Plc. - HPTX
BusinessWire - Mon Apr 20, 3:47PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion" or the "Company" (Nasdaq:HPTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Horizon Pharma, Plc. ("Horizon" (Nasdaq:HZNP) for approximately $1.1 billion. The Company's stockholders will receive $46 in cash for each share of Hyperion common stock they own.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and Intention to Enter Into New Term Loan Facility
Marketwired - Mon Apr 20, 6:23AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" , a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary (the "Issuer" , intends, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2023, and that Horizon Pharma, Inc., the parent of the Issuer and a wholly-owned subsidiary of Horizon ("HPI" , intends to enter into a new term loan facility in an aggregate principal amount of $500 million.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 10.98 (+0.12), AZN: 33.99 (+0.15), HZNP: 20.05 (+1.16), TEVA: 53.27 (-0.34), EGRX: 46.57 (+3.43), HPTX: 45.99 (+0.02)
Stratos Group Adds Life Sciences Leader to Advisory Board
PR Newswire - Thu Nov 19, 2:21PM CST
Stratos Group today announced the addition of Chris Rivera to its Board as a Life Science Advisor.
HPTX: 45.99 (+0.02)
National Association of Professional Women Inducts Kamal Sigel, Vice President of Hyperion Therapeutics, Inc., Into its VIP Professional Woman of the Year Circle
PRWeb - Mon Aug 10, 11:01PM CDT
The National Association of Professional Women (NAPW) honors Kamal Sigel as a 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized with this prestigious distinction for leadership in business. NAPW is the nation's leading networking organization exclusively for professional women, boasting more than 700,000 members and over 200 operating Local Chapters.
HPTX: 45.99 (+0.02)
Hepatic Encephalopathy Therapeutics Pipeline Review, H1 2015 - 4 Companies & 5 Drug Profiles
M2 - Mon Jun 08, 10:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/std5dn/hepatic) has announced the addition of the "Hepatic Encephalopathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Hyperion Therapeutics, Inc. - Ocera Therapeutics, Inc. - Umecrine Cognition AB Drug Profiles - CVXL-0060 - glycerol phenylbutyrate - ornithine phenylacetate - rifaximin - THDP-17 For more information visit http://www.researchandmarkets.com/research/std5dn/hepatic
OCRX: 2.57 (-0.03), HPTX: 45.99 (+0.02)
Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 2:08PM CDT
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2015 earnings of $1.65 per share, substantially lower than the Zacks Consensus Estimate of $1.95.
JAZZ: 150.53 (-0.44), CNCE: 11.82 (+0.33), HPTX: 45.99 (+0.02)
ARIAD (ARIA) Q1 Loss Wider than Estimates; Iclusig Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 10:20AM CDT
ARIAD Pharmaceuticals (ARIA) reported a first-quarter 2015 loss of 28 cents per share, a penny wider than the Zacks Consensus Estimate of a loss of 27 cents.
VRX: 20.95 (+0.06), PFE: 36.90 (-0.41), ARIA: 9.68 (-0.03), HPTX: 45.99 (+0.02)
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 07, 2:45PM CDT
Horizon Pharma (HZNP) is scheduled to report first-quarter 2015 results before the opening bell on May 8.
IPXL: 31.15 (-0.27), ACT: 298.98 (-2.94), HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Completes Acquisition of Hyperion Therapeutics, Inc.
Marketwired - Thu May 07, 11:45AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has completed the acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX).
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma to acquire all outstanding common stock of Hyperion Therapeutics in tender offer at USD46.00 per share
M2 - Thu May 07, 3:06AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) on Thursday updated the results of its tender offer to acquire all of the outstanding shares of common stock of Hyperion Therapeutics (NASDAQ: HPTX) for USD46.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, if any.
HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Results of Tender Offer
Marketwired - Thu May 07, 1:45AM CDT
Horizon Pharma plc ("Horizon"
(NASDAQ: HZNP) today announced the results of its tender offer to purchase all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. ("Hyperion" (NASDAQ: HPTX) for $46.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, if any. The tender offer is being effected by Horizon's indirect subsidiary, Ghrian Acquisition Corp. HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Waiver of Financing Proceeds Condition
Marketwired - Thu Apr 30, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that its affiliates, Horizon Pharma, Inc. ("Parent"
and Ghrian Acquisition, Inc. ("Purchaser" , waived the "Financing Proceeds Condition" described in the Offer to Purchase in connection with the previously announced tender offer to acquire all of the outstanding shares of common stock of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) ("Hyperion" for $46.00 per share in cash, net to the seller in cash, without interest and less any applicable withholding taxes, if any. The tender offer is scheduled to expire at 12:01 a.m. (New York City time) on Thursday, May 7, 2015, unless further extended or earlier terminated. All other terms and conditions of the tender offer remain unchanged, including, without limitation, the "Minimum Condition" described in the Offer to Purchase. HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma reports expiry of HSR Waiting Period for planned acquisition of Hyperion Therapeutics
M2 - Thu Apr 30, 3:07AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) reported on Wednesday the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"
with respect to its proposed acquisition of Hyperion Therapeutics (NasdaqGS:HPTX). HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Expiration of HSR Waiting Period for Proposed Hyperion Therapeutics, Inc. Acquisition
Marketwired - Wed Apr 29, 4:48PM CDT
Horizon Pharma plc (NASDAQ: HZNP) today announced the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"
expired effective Tuesday, April 28, 2015 with respect to its proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX). HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Pricing of Private Offering of Senior Notes
Marketwired - Fri Apr 24, 3:05PM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon"
, a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary (the "Issuer" , has priced its offering of $475 million aggregate principal amount of 6.625% senior notes due 2023. The note offering is expected to close on or about April 29, 2015. The size of the offering was increased above the previously-announced size of $300 million aggregate principal amount of notes. As a result of the increased size of the note offering, Horizon Pharma, Inc. ("HPI" , the parent of the Issuer and a wholly-owned subsidiary of Horizon, expects that the aggregate principal amount of its previously-announced new term loan facility will be reduced from $500 million to $400 million. HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion Therapeutics, Inc. Over the Proposed Sale of the Company to Horizon Pharma, Plc. - HPTX
BusinessWire - Mon Apr 20, 3:47PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion" or the "Company"
(Nasdaq:HPTX) for potential breaches of fiduciary duties in connection with the sale of the Company to Horizon Pharma, Plc. ("Horizon" (Nasdaq:HZNP) for approximately $1.1 billion. The Company's stockholders will receive $46 in cash for each share of Hyperion common stock they own. HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
Horizon Pharma plc Announces Proposed Private Offering of Senior Notes and Intention to Enter Into New Term Loan Facility
Marketwired - Mon Apr 20, 6:23AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon"
, a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced that Horizon Pharma Financing Inc., its wholly-owned subsidiary (the "Issuer" , intends, subject to market and other considerations, to offer $300 million aggregate principal amount of senior notes due 2023, and that Horizon Pharma, Inc., the parent of the Issuer and a wholly-owned subsidiary of Horizon ("HPI" , intends to enter into a new term loan facility in an aggregate principal amount of $500 million. HZNP: 20.05 (+1.16), HPTX: 45.99 (+0.02)
3 Top Healthcare Stocks Surging Higher This Year
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 18, 11:03AM CDT
Aging baby boomers and an increasingly insured population are driving healthcare utilization higher, and that has made stocks in this industry some of the market's best performers over the past three years. A number of healthcare stocks are soaring...
ESPR: 10.98 (+0.12), AZN: 33.99 (+0.15), HZNP: 20.05 (+1.16), TEVA: 53.27 (-0.34), EGRX: 46.57 (+3.43), HPTX: 45.99 (+0.02)
